Author:
Kutsch Nadine,Bahlo Jasmin,Robrecht Sandra,Franklin Jeremy,Zhang Can,Maurer Christian,De Silva Nisha,Lange Elisabeth,Weide Rudolf,Kiehl Michael G.,Sökler Martin,Schlag Rudolf,Vehling-Kaiser Ursula,Köchling Georg,Plöger Christoph,Gregor Michael,Plesner Torben,Herling Marco,Fischer Kirsten,Döhner Hartmut,Kneba Michael,Wendtner Clemens-Martin,Klapper Wolfram,Kreuzer Karl-Anton,Böttcher Sebastian,Stilgenbauer Stephan,Fink Anna Maria,Hallek Michael,Eichhorst Barbara
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference31 articles.
1. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial;Moreno;Lancet Oncol.,2018
2. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL;Woyach;N Engl J Med.,2018
3. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia;Shanafelt;N Engl J Med.,2019
4. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial;Fischer;Blood.,2016
5. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia;Thompson;Blood.,2016